This week in Drug Discovery (23 – 27 February)
News round-up for 23 – 27 February by Bruno Quinney, Content Team at DDW.
This week in drug discovery, more effective treatments have been found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research.
The top stories:
Injectable HIV drug more effective than daily oral therapy
Results from the LATITUDE study of Cabenuva (cabotegravir + rilpivirine), a long-acting injectable developed by HIV specialist ViiV Healthcare, show the switch to the injectable reduced risk of virological failure by nearly half compared to daily oral therapy.
Read more…
Gel could heal chronic wounds seven times faster, data shows
Biotechnology company SolasCure has released data from its Phase II trial of the Aurase Wound Gel (AWG), showing the gel demonstrated 22 times faster debridement and seven times faster healing compared to standard of care.
NICE recommends first bispecific antibody to treat lymphoma
Tepkinly (epcoritamab), developed by biopharmaceutical company AbbVie, has been recommended to the NHS as an option to treat adult patients with follicular lymphoma whose cancer has returned or who have not responded to at least two prior treatments.
Boost in trial activity would have huge gains, report says
A report from the European Federation of Pharmaceutical Industries and Associations (EFPIA) highlights increasing clinical trial activity across Europe would have significant health, economic and productivity returns.
Read more…
EANM launches award for prostate cancer research
The 2026 EANM Young Scientist Network Award, aiming to accelerate innovation in alpha radioligand therapy in prostate cancer, offers three prizes of €40,000 (Platinum), €20,000 (Gold) and €10,000 (Silver).